Goodwin Biotechnology is becoming GBI and expanding to launch a brand-new, larger-capacity cGMP biologics facility.   Though the name may change, GBI’s mission remains the same: from clinical to commercial products, providing high-quality, cost-effective, flexible, and timely cGMP-compliant manufacturing solutions to eliminate the manufacturing risk for companies developing complex biotherapeutics.   GBI says it is as committed as ever to bringing its decades of experience to new and existin...